dexamethasone 21-phosphate has been researched along with Pulmonary Disease, Chronic Obstructive in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ito, K; Iwamoto, I; Kimura, G; Kizawa, Y; Nishimoto, Y; Suzuki, A; Ueda, K | 1 |
| Antonelli, A; Bianchi, M; Chiarantini, L; Crinelli, R; Fraternale, A; Magnani, M; Rossi, L | 1 |
2 other study(ies) available for dexamethasone 21-phosphate and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
[TNF-α Decreased Corticosteroid Responsiveness in Mice Models of Airway Inflammation Induced by Double Strand RNA and/or Tobacco Smoke Exposure].
Topics: Administration, Intranasal; Animals; Antibodies; Dexamethasone; Disease Models, Animal; Drug Resistance; Environmental Exposure; Glucocorticoids; Inflammation; Male; Mice, Inbred A; Molecular Targeted Therapy; Nicotiana; Pulmonary Disease, Chronic Obstructive; RNA, Double-Stranded; Signal Transduction; Smoking; Tumor Necrosis Factor-alpha | 2019 |
Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides.
Topics: Cystic Fibrosis; Dexamethasone; Drug Delivery Systems; Erythrocytes; Genetic Therapy; Half-Life; Humans; Macrophages; Oligonucleotides; Pulmonary Disease, Chronic Obstructive; Recombinant Proteins | 2002 |